HK1252099A1 - 焦谷氨酸沃替西汀 - Google Patents

焦谷氨酸沃替西汀

Info

Publication number
HK1252099A1
HK1252099A1 HK18111409A HK18111409A HK1252099A1 HK 1252099 A1 HK1252099 A1 HK 1252099A1 HK 18111409 A HK18111409 A HK 18111409A HK 18111409 A HK18111409 A HK 18111409A HK 1252099 A1 HK1252099 A1 HK 1252099A1
Authority
HK
Hong Kong
Prior art keywords
vortioxetine pyroglutamate
vortioxetine
pyroglutamate
Prior art date
Application number
HK18111409A
Other languages
English (en)
Other versions
HK1252099B (zh
Inventor
Lopez De Diego Heidi
Lasse Christensen Kim
Holm Rene
Kateb Jens
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55963369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1252099(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of HK1252099A1 publication Critical patent/HK1252099A1/zh
Publication of HK1252099B publication Critical patent/HK1252099B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK18111409.2A 2015-05-13 2018-09-05 焦谷氨酸沃替西汀 HK1252099B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201500284 2015-05-13
PCT/EP2016/060540 WO2016180870A1 (en) 2015-05-13 2016-05-11 Vortioxetine pyroglutamate

Publications (2)

Publication Number Publication Date
HK1252099A1 true HK1252099A1 (zh) 2019-05-17
HK1252099B HK1252099B (zh) 2020-02-07

Family

ID=55963369

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111409.2A HK1252099B (zh) 2015-05-13 2018-09-05 焦谷氨酸沃替西汀

Country Status (43)

Country Link
US (2) US10287261B2 (zh)
EP (1) EP3294719B1 (zh)
JP (1) JP6731001B2 (zh)
KR (1) KR102551429B1 (zh)
CN (1) CN107567440B (zh)
AR (1) AR104591A1 (zh)
AU (1) AU2016259762B2 (zh)
BR (1) BR112017024039B8 (zh)
CA (1) CA2984615C (zh)
CL (1) CL2017002844A1 (zh)
CO (1) CO2017011295A2 (zh)
CR (1) CR20170506A (zh)
CY (1) CY1121171T1 (zh)
DK (1) DK3294719T3 (zh)
DO (1) DOP2017000260A (zh)
EA (1) EA032363B1 (zh)
EC (1) ECSP17074919A (zh)
ES (1) ES2709362T3 (zh)
GE (1) GEP20197020B (zh)
HK (1) HK1252099B (zh)
HR (1) HRP20190089T1 (zh)
HU (1) HUE042893T2 (zh)
IL (1) IL255466B (zh)
JO (1) JO3456B1 (zh)
LT (1) LT3294719T (zh)
MA (1) MA43397A (zh)
ME (1) ME03312B (zh)
MX (1) MX2017014390A (zh)
MY (1) MY184965A (zh)
PE (1) PE20180039A1 (zh)
PH (1) PH12017502028A1 (zh)
PL (1) PL3294719T3 (zh)
PT (1) PT3294719T (zh)
RS (1) RS58263B1 (zh)
RU (1) RU2713889C2 (zh)
SI (1) SI3294719T1 (zh)
SV (1) SV2017005560A (zh)
TN (1) TN2017000453A1 (zh)
TR (1) TR201901228T4 (zh)
TW (1) TWI700276B (zh)
UA (1) UA120779C2 (zh)
WO (1) WO2016180870A1 (zh)
ZA (1) ZA201707337B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201806599A (zh) 2016-07-01 2018-03-01 Ｈ 朗德貝克公司 用於快速開始抗抑鬱作用之給藥方案
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
US11020390B2 (en) 2017-02-17 2021-06-01 Unichem Laboratories Ltd Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
EP3532457B1 (en) * 2017-07-31 2020-03-18 Small Pharma Ltd Crystalline forms of hydroxynorketamine
GB201715950D0 (en) * 2017-10-02 2017-11-15 Croda Int Plc Gel composition comprising a phase change material
WO2021198778A1 (en) 2020-04-03 2021-10-07 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1006728A (en) * 1962-12-31 1965-10-06 Mundipharma Ag Amine salts of pyrrolidone carboxylic acid
JPS6160620A (ja) 1984-09-03 1986-03-28 Teijin Ltd ピログルタミン酸エステル類を含有する医薬品組成物
US4780667A (en) 1985-06-25 1988-10-25 Hewlett-Packard Company Magnetostatic wave delay line discriminator with automatic quadrature setting and automatic calibration
FR2694194B1 (fr) 1992-07-31 1994-11-04 Health Business Dev Gel hydratant, médicament et composition cosmétique le contenant, procédé de préparation dudit gel.
WO1998006385A1 (de) 1996-08-15 1998-02-19 Losan Pharma Gmbh Gut schluckbare orale arzneiform
US6436946B1 (en) * 1997-05-02 2002-08-20 Morris A. Mann Xanthine-containing compositions for oral administration and uses related thereto
SK284948B6 (sk) 2000-04-06 2006-03-02 Zentiva, A. S. Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US8383154B2 (en) 2004-05-11 2013-02-26 Egalet A/S Swellable dosage form comprising gellan gum
EP2044043B2 (en) * 2006-06-16 2021-03-03 H. Lundbeck A/S 1- ý[- (2, 4-dimethylphenylsulfanyl) -phenyl]piperazine hydrobromide as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
MX2011011119A (es) * 2009-04-24 2011-11-04 Lundbeck & Co As H Formulaciones liquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil) fenil] piperazina.
UA105057C2 (uk) 2009-08-24 2014-04-10 Х. Луннбек А/С Композиція 1-[2-(2,4-диметилфенілсульфаніл)феніл]-піперазину
MA34261B1 (fr) * 2010-04-30 2013-05-02 Takeda Pharmaceutcal Company Ltd Comprime a delitage intestinal
CN104797566B (zh) * 2012-09-19 2017-07-07 桑多斯股份公司 沃替西汀氢溴酸盐的新结晶形式
EP2958903B1 (en) 2013-02-22 2017-04-12 H. Lundbeck A/S Vortioxetine manufacturing process

Also Published As

Publication number Publication date
BR112017024039A2 (pt) 2018-07-24
PL3294719T3 (pl) 2019-04-30
TN2017000453A1 (en) 2019-04-12
IL255466B (en) 2022-07-01
DK3294719T3 (en) 2019-02-25
LT3294719T (lt) 2019-02-11
PH12017502028A1 (en) 2018-04-02
KR20180006909A (ko) 2018-01-19
WO2016180870A1 (en) 2016-11-17
BR112017024039B8 (pt) 2023-10-31
SI3294719T1 (sl) 2019-03-29
ECSP17074919A (es) 2018-02-28
MX2017014390A (es) 2018-03-23
TWI700276B (zh) 2020-08-01
CN107567440A (zh) 2018-01-09
JP2018515520A (ja) 2018-06-14
JP6731001B2 (ja) 2020-07-29
UA120779C2 (uk) 2020-02-10
BR112017024039B1 (pt) 2023-07-04
AR104591A1 (es) 2017-08-02
AU2016259762B2 (en) 2020-03-19
PE20180039A1 (es) 2018-01-09
PT3294719T (pt) 2019-02-07
RU2713889C2 (ru) 2020-02-10
CR20170506A (es) 2018-02-08
RS58263B1 (sr) 2019-03-29
CY1121171T1 (el) 2020-05-29
CL2017002844A1 (es) 2018-05-11
EA201792262A1 (ru) 2018-04-30
EA032363B1 (ru) 2019-05-31
HK1252099B (zh) 2020-02-07
US11279682B2 (en) 2022-03-22
HRP20190089T1 (hr) 2019-02-22
DOP2017000260A (es) 2018-02-28
HUE042893T2 (hu) 2019-07-29
EP3294719B1 (en) 2019-01-02
MA43397A (fr) 2018-03-21
US20190210987A1 (en) 2019-07-11
TW201706255A (zh) 2017-02-16
US10287261B2 (en) 2019-05-14
TR201901228T4 (tr) 2019-02-21
CA2984615A1 (en) 2016-11-17
RU2017139002A3 (zh) 2019-08-30
CN107567440B (zh) 2021-06-22
RU2017139002A (ru) 2019-06-13
SV2017005560A (es) 2018-02-23
GEP20197020B (en) 2019-09-25
CA2984615C (en) 2023-06-13
ME03312B (me) 2019-10-20
ZA201707337B (en) 2019-02-27
IL255466A (en) 2018-01-31
EP3294719A1 (en) 2018-03-21
KR102551429B1 (ko) 2023-07-04
JO3456B1 (ar) 2020-07-05
CO2017011295A2 (es) 2018-02-20
AU2016259762A1 (en) 2017-11-16
US20160368884A1 (en) 2016-12-22
MY184965A (en) 2021-04-30
ES2709362T3 (es) 2019-04-16

Similar Documents

Publication Publication Date Title
DK3256580T3 (en) Cysteinprotease
GB201506824D0 (en) TrailReach Multitrial
HRP20190089T1 (hr) Vortioksetin piroglutamat
DK3324768T3 (en) Tørdragt
HK1251001A1 (zh) Il-37變體
GB201511039D0 (en) In-vitro-analyser
AU361999S (en) Ballustrade
GB201617732D0 (en) Corbel-Pro
GB2541249B (en) Hole-saw
GB201522365D0 (en) Concept abcd12
GB201518520D0 (en) Concept ABCD4
AU366552S (en) Nutblock
GB201522111D0 (en) Balaclavas
GB201521340D0 (en) Snapshop
GB201518875D0 (en) Drydam
GB201515216D0 (en) Concept B
GB201516026D0 (en) Rencu
GB201515751D0 (en) DinoMania
GB201514277D0 (en) Tippex
GB201511795D0 (en) CeltOme
GB201506176D0 (en) Concept concept
AU2015165V (en) PWBC12 Chamelaucium uncinatum
GB201510409D0 (en) Rd9115
AU362754S (en) Playsuit
GB201510064D0 (en) Pipecutter